In conclusion, the efficacy of risk-based breast cancer screening practices, such as MRI, for BRCA1 and BRCA2 mutation carriers shows promise in terms of increased cancer detection rates and decreased mortality. This evidence concerns the gene BRCA2 and breast carcinoma.